Arena Pharmaceuticals

(ARNA) - Get Report

has a classic series of products with a lot of ways to win," said Jim Cramer on his

"RealMoney" radio show Wednesday.

Drugmakers have seen a lot of consolidation, he told one caller.



did it a long time ago, and now



is bidding on




Arena, which Cramer says is one of his favorite stocks, "represents the future." Big pharma companies often just buy new drugs for their pipeline instead of developing their own, and if Arena's deal with

Johnson & Johnson

(JNJ) - Get Report

company Ortho-McNeill for insulin products takes off, J&J will just buy the company, Cramer said.

"Arena is a good stock to own because it will be bought," and at about $14, there's a lot of upside, Cramer said.

Companies like

TJ Maxx

(TJX) - Get Report


Limited Brands


keep doing well and grinding out sales, Cramer told one caller who asked whether to stay with TJ through the holiday season.

"If I had 100 shares, I'd take off 25, but the future is very bright for TJX," he said.

"I would hold onto


(DIS) - Get Report

. I would not sell the stock," Cramer told another caller who bought shares of the company ten years ago and wondered about getting rid of it.

Under Michael Eisner, management was bad, Cramer said. But Robert Iger, "the guy who runs it now, is starting to a lot of right things." Plus, now that gas prices are lower, more people will be visiting Disneyland and Disney World, Cramer said.



is "getting its butt kicked by


(CSCO) - Get Report

," Cramer told another caller. "If you could buy ten shares of Cisco rather than 100 shares of Nortel, you'd do much better," he said.

Cisco has crushed Nortel and



, and has taken business away from them, Cramer said.

"Nortel and Lucent should be avoided at all costs," and Cramer believes that they must be sold because they're not going any higher.

To see the most recent edition of The RealMoney Radio Recap in its entirety, please click here. This recap is published every day around 3 p.m. ET.

At the time of publication, Cramer was long Johnson & Johnson.

Jim Cramer is a director and co-founder of TheStreet.com. He contributes daily market commentary for TheStreet.com's sites and serves as an adviser to the company's CEO. Outside contributing columnists for TheStreet.com and RealMoney.com, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for

Action Alerts PLUS. Listen to Cramer's RealMoney Radio show on your computer; just click

here. Watch Cramer on "Mad Money" at 6 p.m. ET weeknights on CNBC. Click

here to order Cramer's latest book, "Real Money: Sane Investing in an Insane World," click

here to get his second book, "You Got Screwed!" and click

here to order Cramer's autobiography, "Confessions of a Street Addict." While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by

clicking here.

TheStreet.com has a revenue-sharing relationship with Traders' Library under which it receives a portion of the revenue from Traders' Library purchases by customers directed there from TheStreet.com.